- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01184053
Trisenox® in Women With Metastatic Endometrial Cancer (NRR)
A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma
Study Overview
Detailed Description
This is an open-label, single arm, single institution, phase II trial designed to assess the response rate and safety of Trisenox® in women with recurrent endometrial carcinoma. Trisenox® will be administered at a dose of 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks. A 4-week period will be defined as a cycle of treatment. Marker and non-marker lesions will be assessed every 2 cycles (every 8 weeks) and the response assigned according to Gynecologic Oncology Group (GOG) RECIST guidelines. Safety will be assessed by routine physical, laboratory and ECG evaluations. Up to 10 patients will be enrolled into the study. Patients are expected (excluding any unforeseen toxicities) to receive a minimum of 2 and a maximum of 6 cycles of Trisenox®. (Patients with at least documented stable disease may be eligible for >6 cycles). Patients will be followed for 6 months after their last dose of Trisenox®.
For this trial we would allow one prior cytotoxic regimen since the time of recurrence and patients may have had one prior regimen as part of their induction chemotherapy. Patients will be treated with 0.25 mg/kg/day for days 1-5 every 28 days and patients may remain on trial until progression of disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- North Carolina Cancer Hosptial, UNC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 years of age with histologically confirmed metastatic or recurrent endometrial cancer
- Documented progression of their endometrial cancer (i.e., within the last 3 months)
- If of childbearing potential they must agree to use approved barrier methods of contraception
Presence of at least one measurable lesion that:
- Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral CT scan (or otherwise at least twice the reconstruction interval for CT or MRI scans).
- Previously irradiated lesions may be considered to be measurable provided: 1) there has been documented progression of the lesion(s) since completion of radiotherapy, and 2) the criteria for measurability as outlined above are met.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Minimum life expectancy of 3 months
- Adequate renal and hepatic function (per study protocol guidelines)
- Adequate bone marrow function (per study protocol guidelines)
- Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL
- Able to understand and give written informed consent
- Ejection fraction >55% with no focal left ventricular wall motion abnormalities in patients with a history of coronary artery disease or a history of congestive heart failure.
Exclusion Criteria:
- Women who are pregnant or lactating
- Presence of brain metastases
- Two or more prior cycles of cytotoxic chemotherapy since recurrence (Two total regimens are allowed if one includes adjuvant therapy.)
- Prior therapy with Trisenox or known sensitivity to this agent
- Prior anticancer treatment (chemotherapy, radiotherapy, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of Trisenox.
- Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by NCI toxicity criteria)
- Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
- Significant uncontrolled cardiovascular disease
- Active infection requiring systemic therapy
- Known HIV infection
- Treatment with any investigational agent within 4 weeks prior to the first dose of Trisenox
- Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids
- Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of Trisenox
- Patients having undergone recent placement of a central venous access port will be considered eligible if they have recovered
- Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug
- Prolonged absolute corrected QT interval (QTc) interval > 500 msec
- Underlying conduction disease that prevents measurement of QT interval
- History of ventricular tachycardia or any cardiac arrhythmia requiring the placement of an automated intraventricular cardiac defibrillator.
- Inability to discontinue therapy with class I or class III antiarrhythmic medications.
- Inability to discontinue drugs known to be associated with a risk for torsades de pointes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trisenox treatment
Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
|
Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response (CR+PR) Rate of Subjects Given Trisenox
Time Frame: 28 days
|
To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group [GOG] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 5 years
|
5 years
|
|
Progression Free Survival in Patients Treated With Trisenox®
Time Frame: 28 days
|
Progression-Free survival is the period from start of treatment until disease progression, death, or date of last contact.
|
28 days
|
Associations Between Markers of Angiogenesis (e.g. VEGF) With Response
Time Frame: 4 years
|
We will request a blood sample to measure vascular endothelial growth factor (VEGF) as well as other angiogenic factors and correlate levels to response to arsenic trioxide.
Such effects have been observed in cultured cell lines and animal models, as well as clinical studies.
|
4 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Paola Gehrig, MD, UNC Lineberger Comprehensive Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC 0920
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Carcinoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAtypical Endometrial Hyperplasia | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IA Endometrial Carcinoma | Stage IB Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage... and other conditions
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditionsCanada
-
Case Comprehensive Cancer CenterTerminatedStage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage I Endometrial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Endometrial Adenosquamous Cell Carcinoma | Endometrial AdenoacanthomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
National Cancer Institute (NCI)NRG Oncology; Canadian Cancer Trials GroupActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditionsUnited States, Korea, Republic of, Canada, Puerto Rico, Japan
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IV Endometrial CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingEndometrial Cancer | Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage III Endometrial Cancer | Endometrial Carcinoma Stage IIIUnited States
Clinical Trials on Arsenic trioxide
-
Ruijin HospitalRecruitingRefractory Solid TumorsChina
-
CTI BioPharmaTerminatedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | LeukemiaUnited States, Canada, Australia
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Extragonadal Germ Cell TumorUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedLymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Completed